Enviral
Generic Name
Enviradine
Manufacturer
MediCorp Pharma
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| enviral 1 mg tablet | ৳ 90.95 | ৳ 1,273.30 |
Description
Overview of the medicine
Enviral 1 mg tablet contains Enviradine, a direct-acting antiviral indicated for the treatment of chronic viral hepatitis C (HCV) infection in adults.
Uses & Indications
Dosage
Adults
The recommended dose is 1 mg orally once daily, with or without food, for a duration specified by the physician, typically 12 or 24 weeks depending on genotype and treatment history.
Elderly
No dose adjustment is typically required for elderly patients (≥65 years of age) based on age alone.
Renal_impairment
For severe renal impairment (eGFR <30 mL/min) or end-stage renal disease requiring dialysis, the dose should be reduced to 0.5 mg once daily. No adjustment needed for mild to moderate impairment.
How to Take
Take the tablet orally, once daily, with or without food. Swallow the tablet whole; do not crush, chew, or break it. For optimal absorption, it is often recommended to take it at the same time each day.
Mechanism of Action
Enviradine is a potent and selective inhibitor of the HCV NS5B RNA-dependent RNA polymerase, essential for viral replication. It directly blocks the enzyme's activity, thereby preventing the synthesis of new viral RNA.
Pharmacokinetics
Onset
Initiation of viral load reduction typically observed within 24-48 hours of first dose.
Excretion
Mainly excreted via the feces (approximately 80%), with a smaller portion excreted in the urine (approximately 15%).
Half life
The elimination half-life is approximately 12-15 hours, allowing for once-daily dosing.
Absorption
Rapidly absorbed from the gastrointestinal tract, reaching peak plasma concentrations within 1-2 hours. Bioavailability is approximately 60-70%.
Metabolism
Primarily metabolized in the liver by cytochrome P450 3A4 (CYP3A4).
Side Effects
Contraindications
- •Hypersensitivity to Enviradine or any component of the tablet.
- •Severe hepatic impairment (Child-Pugh C) without specific dose adjustment guidelines.
Drug Interactions
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)
May increase Enviradine plasma concentrations, potentially increasing the risk of adverse effects. Dose adjustment or careful monitoring may be necessary.
Strong CYP3A4 Inducers (e.g., Rifampin, Carbamazepine, Phenytoin)
May significantly decrease Enviradine plasma concentrations, leading to reduced efficacy. Co-administration is not recommended.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, no specific antidote is available. Management should consist of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. Hemodialysis is unlikely to remove a significant amount of Enviradine.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have not shown a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed and the potential benefit outweighs the potential risk to the fetus. It is unknown whether Enviradine is excreted in human milk; caution is advised when administered to a nursing mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months from the date of manufacture.
Availability
Pharmacies nationwide
Approval Status
Approved by regulatory bodies
Patent Status
Under patent protection
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
